<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02940925</url>
  </required_header>
  <id_info>
    <org_study_id>20160049</org_study_id>
    <nct_id>NCT02940925</nct_id>
  </id_info>
  <brief_title>TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma</brief_title>
  <official_title>TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma, a Prospective,Parallel, Randomized, Open Labeled, Multicenter Phase III Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the survival and toxicity of TPC (TAXOL, DDP AND
      CAPECITABINE ) VS PF (cisplatin and 5-Fluorouracil) as induction chemotherapy combined with
      concurrent chemoradiotherapy (CCRT) for stage IVa-b nasopharyngeal carcinoma patients in
      endemic area.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, parallel, randomized, open labeled, multicenter phase III clinical
      trial to compare the survival and toxicity of TPC VS PF as induction chemotherapy combined
      with CCRT for stage IVa-b nasopharyngeal carcinoma patients in endemic area.The primary
      endpoint is failure free survival (FFS）.The secondary endpoints are overall
      survival(OS）,progression-free survival（PFS）, local-regionally relapse free survival(LRFS),
      distant metastasis free survival（DMFS)and toxicities.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure-free survival calculated from randomisation to locoregional failure, distant failure, or death from any cause</measure>
    <time_frame>up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival calculated from randomisation to death from any cause</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival calculated from randomisation to disease progression or death from any cause</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local-regionally relapse free survival calculated from randomisation to locoregional failure</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis free survival calculated from randomisation to distant failure</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Drug: Taxol,cisplatin and capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taxol, cisplatin and capecitabine as induction chemotherapy (IC) combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy |(CCRT).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: Cisplatin and 5-Fluorouracil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Drug: Taxol,cisplatin and capecitabine</intervention_name>
    <description>Taxol, cisplatin and capecitabine as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.</description>
    <arm_group_label>Drug: Taxol,cisplatin and capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Drug: Cisplatin and 5-Fluorouracil</intervention_name>
    <description>Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.</description>
    <arm_group_label>Drug: Cisplatin and 5-Fluorouracil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  WHO II or III pathological type

          -  stage Ⅳa or Ⅳb (UICC 7th edition)

          -  no anticancer treatment before

          -  no malignant history

          -  both gender, 18-60 years old

          -  enough liver function: TBIL≤ULN；AST/ALT≤2.5×ULN；ALP≤5×ULN

          -  enough kidney function: Clcr≥80 mL/min

          -  enough hemo: ANC≥2×109/L, PLT≥100×109/L and HB≥9g/dL

          -  no sever heart, lung disfunction

          -  PS≤2

        Exclusion Criteria:

          -  previous anticancer treatment

          -  distant metastasis

          -  pregnant or breasting female

          -  can not access to followup

          -  enrolled in other therapeutic clinical trial

          -  sever infection and internal disease

          -  sever disfunction of heart, lung, kidney, liver, etc

          -  TBIL&gt;ULN；AST/ALT&gt;2.5×ULN；ALP&gt;5×ULN

          -  with factors that will affect the administration, distribution,metabolism or
             evacuation.

          -  using immunosuppressive agents after organ transplantation

          -  other malignant history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanqun Xiang</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Taize Yuan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Center of Guangzhou medical school</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yunxiang He</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiangya Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weixiong Xia</last_name>
    <phone>+86-18520415699</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xing Lv</last_name>
    <phone>+86-15920182400</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>SunYat-senU</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanqun Xiang, MD</last_name>
      <phone>+86-18666096623</phone>
      <email>xiangyq@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Weixiong Xia, MD</last_name>
      <phone>+86-18520415699</phone>
      <email>xiawx@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, Yu BK, Chiu SK, Kwan WH, Ho R, Chan I, Ahuja AT, Zee BC, Chan AT. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009 Jan 10;27(2):242-9. doi: 10.1200/JCO.2008.18.1545. Epub 2008 Dec 8.</citation>
    <PMID>19064973</PMID>
  </reference>
  <reference>
    <citation>Chan AT, Ma BB, Lo YM, Leung SF, Kwan WH, Hui EP, Mok TS, Kam M, Chan LS, Chiu SK, Yu KH, Cheung KY, Lai K, Lai M, Mo F, Yeo W, King A, Johnson PJ, Teo PM, Zee B. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol. 2004 Aug 1;22(15):3053-60.</citation>
    <PMID>15284255</PMID>
  </reference>
  <reference>
    <citation>Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1695-704.</citation>
    <PMID>17960012</PMID>
  </reference>
  <reference>
    <citation>Lee AW, Ngan RK, Tung SY, Cheng A, Kwong DL, Lu TX, Chan AT, Chan LL, Yiu H, Ng WT, Wong F, Yuen KT, Yau S, Cheung FY, Chan OS, Choi H, Chappell R. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 2015 Apr 15;121(8):1328-38. doi: 10.1002/cncr.29208. Epub 2014 Dec 19.</citation>
    <PMID>25529384</PMID>
  </reference>
  <reference>
    <citation>Gao Y, Huang HQ, Bai B, Cai QC, Wang XX, Cai QQ. Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy. Expert Opin Pharmacother. 2014 Feb;15(2):163-71. doi: 10.1517/14656566.2014.866652. Epub 2013 Dec 3.</citation>
    <PMID>24295173</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2016</study_first_submitted>
  <study_first_submitted_qc>October 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2016</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>XIANG YANQUN</investigator_full_name>
    <investigator_title>PROFESSOR</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal carcinoma</keyword>
  <keyword>induction chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The diagnosis, treatment regimen, toxicity and followup data will be shared once every year through email, phone or meeting.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

